The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines

NCT ID: NCT01203319

Last Updated: 2012-04-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 1091 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2011-03-31

Brief Summary

This study is an expanded Phase 2/Phase 3 clinical trial base on the safety data obtained from the phase 1 clinical trial. The purpose of this study is to further evaluate the immunogenicity and safety of 60mcg/30mcg recombinant hepatitis B vaccines in people aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines and to explore the optimizing immunizing dose and immune procedure.

Detailed Description

The most effective method to prevent hepatitis B virus infection is to receive the vaccination of hepatitis b vaccine to get the protective antibody anti-HBs. Both the blood-derived hepatitis B vaccine and the recombinant hepatitis B vaccines have been proved to be effective and safe since the application in 1981 and 1989 respectively. Previous passive or active immunization testes indicated that the lowest effective level of anti-HBs for prevention of infection is 10mIU/ml. However there are still some recipients can't generate expected level of anti-HBs after the vaccinations. In adults, there are 5% to 10% recipients will failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines, and those nonresponders are susceptible population even after the vaccinations. In this study, a recipient whose peak period (1 month after vaccination) levels of anti-HBs is lower than 10mIU/ml after finishing the vaccinations of 3 dose 10mcg hepatitis b vaccines is called nonresponders.

Nowadays, a lot tests are conducted on nonresponders to help them generate the protective antibody anti-HBs, including increase the antigen dosage of vaccines, increase the injections of vaccines, change the route of inoculation and the use of adjuvant. Unfortunately, these previous studies can not get coincident and persuasive outcomes due to the small sample size and poor representativeness. This study is plan to evaluate the immunogenicity and safety of 60mcg/30mcg recombinant hepatitis B vaccines in people aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines and to provide the scientific evidences for the revaccination strategy in China.

Conditions

Hepatitis b

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

60mcg/1.0ml recombinant hepatitis B vaccine

600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.

Group Type: EXPERIMENTAL

60mcg/1.0ml recombinant hepatitis B vaccine

Intervention Type: BIOLOGICAL

to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60

30mcg/1.0ml recombinant hepatitis B vaccine

600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.

Group Type: EXPERIMENTAL

30mcg/1.0ml recombinant hepatitis B vaccine

Intervention Type: BIOLOGICAL

to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.

10mcg/1.0ml recombinant hepatitis B vaccine

300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.

Group Type: PLACEBO_COMPARATOR

10mcg/1.0ml recombinant hepatitis B vaccine

Intervention Type: BIOLOGICAL

to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60

Interventions

60mcg/1.0ml recombinant hepatitis B vaccine

to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60

Intervention Type: BIOLOGICAL

30mcg/1.0ml recombinant hepatitis B vaccine

to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.

Intervention Type: BIOLOGICAL

10mcg/1.0ml recombinant hepatitis B vaccine

to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Filter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines:

• Healthy subjects aged 16 and older as established by medical history and clinical examination
• The subjects or their guardians are able to understand and sign the informed consent
• Had never received the hepatitis B vaccines
• Subjects who can and will comply with the requirements of the protocol

Revaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines:

• Healthy subjects aged 16 and older as established by medical history and clinical examination
• The subjects or their guardians are able to understand and sign the informed consent
• After the routine administration of 10mcg hepatitis B vaccines, the peak period levels of anti-HBs is lower than 10mIU/ml
• Subjects with temperature <37.1°C on axillary setting
• Subjects who can and will comply with the requirements of the protocol

Exclusion Criteria

Filter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines:

• Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
• Family history of seizures or progressive neurological disease
• Family history of congenital or hereditary immunodeficiency
• Women of pregnancy, lactation or about to be pregnant in 60 days
• Autoimmune disease or immunodeficiency
• Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws
• Any prior administration of administration of immunoglobulins

Filter period: The subjects to receive second or/and third 10mcg recombinant hepatitis B vaccines:

• Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations
• Serious adverse reactions to vaccines
• Active infections
• Subjects who want to quit the study
• Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Revaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines:

• Qualitative test of Anti-HBs, HBsAg or Anti-HBc on serum is positive
• Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations
• Family history of seizures or progressive neurological disease
• Family history of congenital or hereditary immunodeficiency
• Women of pregnancy, lactation or about to be pregnant in 60 days
• Autoimmune disease or immunodeficiency
• Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws
• Any prior administration of immunoglobulins, any other vaccines or experimental drugs in the last 7days
• Any active infections and received any antibiotic or anti-virus treatments in the last 7 days
• Had a fever in the last 3 days, with temperature ≥37.1°C
• Participate in another clinical trials
• Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Revaccination period: The nonresponders to receive second or/and third 60mcg recombinant hepatitis B vaccines:

• Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations
• Serious adverse reactions to vaccines
• Active infections
• Subjects who want to quit the study
• Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shenzhen Kangtai Biological Products Co., LTD

INDUSTRY

Sponsor Role: collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Feng-Cai Zhu, Master

Role: PRINCIPAL_INVESTIGATOR

Jiangsu Provincial Center for Diseases Control and Prevention

References

Pan HX, Zeng Y, Song XF, Zhang YJ, Xu K, Liang ZL, Zhu FC. Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine. 2014 Jun 17;32(29):3706-12. doi: 10.1016/j.vaccine.2014.02.094. Epub 2014 Mar 27.

Reference Type: DERIVED

PMID: 24681228 (View on PubMed)

Other Identifiers

KT0003

Identifier Type: -

Identifier Source: org_study_id